Cara Therapeutics (CARA) Debt/EBITDA US GAAP (year values) |
||||||||
| 2022 | 2023 | 2023 | 2024 | 2025 | LTM ? | |||
| Debt/EBITDA | 1.71 | 0.47 | 0.49 | 0.61 | 1.14 | 1.14 | ||
| Changes by years, y/y, % | -8% | -72% | +3% | +24% | +89% | |||
Cara Therapeutics. Debt/EBITDA
Cara Therapeutics. Debt/EBITDA, changes, %
Cara Therapeutics (CARA) Debt/EBITDA US GAAP (quarter values) |
||||||||
| 2024Q4 | 2025Q1 | 2025Q2 | 2025Q3 | 2025Q4 | LTM ? | |||
| Debt/EBITDA | 0.61 | 1.01 | 1.64 | 1.83 | 1.14 | 1.14 | ||
| Changes by years, y/y, % | +24% | +398% | +259% | +320% | +89% | |||
| Changes by quarters, q/q, % | +39% | +67% | +63% | +11% | -37% | |||